ABSTRACT
BACKGROUND: With a rise in demand for cosmetic dermatologic procedures comes an increase in nonphysician providers performing such procedures. However, little is known about the practice of cosmetic procedures performed by nonphysicians. OBJECTIVE: To assess the differences in the practice of cosmetic procedures provided by physicians and nonphysicians. MATERIALS AND METHODS: A cross-sectional analysis was performed using participant ( n = 4,062) responses to an 18-point, web-based survey about previous cosmetic procedures. RESULTS: In total, 1,328 participants reported having previous cosmetic procedures done by a physician ( n = 828), a nonphysician ( n = 413), or an unknown provider ( n = 87). Respondents of all age ranges and male respondents ( p < .001) tended to choose physicians over nonphysician providers when choosing a practice. Moderate adverse events were more frequently seen when nonphysician providers completed cosmetic procedures ( p < .001). Despite a higher frequency (73.3% vs 51.8%) of more moderate complications seen in procedures done by nonphysician providers, over 70% of respondents believe that nonphysician providers are qualified enough to continue performing cosmetic procedures. CONCLUSION: People should be encouraged to make an informed decision when choosing a provider because cosmetic procedures are still considered medical procedures.
Subject(s)
Physicians , Humans , Male , Cross-Sectional Studies , Surveys and QuestionnairesABSTRACT
BACKGROUND: Constitutional periorbital dark circles (PDC) are common in skin of color and represent a therapeutic challenge. OBJECTIVE: To summarize the experience of the International Peeling Society on the safety and effectiveness of deep chemical peeling in the treatment of constitutional PDC. MATERIALS AND METHODS: Multi-institutional, retrospective case series (1990-2020) of constitutional PDC treated by deep chemical peeling. Descriptive analysis by age, sex, Fitzpatrick phototype, phenol-croton formula, degree and durability of improvement, and complications. RESULTS: Fifty-five phenol-croton oil peels were performed in 52 patients: 3 patients received a second peel for periorbital rhytids 72 to 84 months after the first peel. 92% (48/52) of patients were women; the median age was 46 years (range, 23-68 years). 89% (46/52) of patients were Fitzpatrick III-IV. Most common formula included phenol 60% to 65% and croton oil 0.6% to 0.7%. 89% (49/55) of peels demonstrated >50% clinical improvement. The median duration of improvement was 24 months (range, 1.5-168 months), and 69% (36/52) of patients demonstrated ongoing improvement at the last follow-up. 4% (2/55) of peels exhibited complications of persistent erythema that resolved without scarring. CONCLUSION: Based on its safety and effectiveness, deep chemical peels are a treatment of choice for constitutional PDC.
Subject(s)
Chemexfoliation , Croton , Humans , Female , Middle Aged , Male , Croton Oil , Retrospective Studies , PhenolsABSTRACT
BACKGROUND: Actinic keratoses (AKs) are a common premalignant cutaneous neoplasm and can progress to squamous cell carcinoma. A variety of treatment options are available for field therapy of diffuse AKs. OBJECTIVE: This review systematically analyzes the use of chemical peels for treatment of AKs. MATERIALS AND METHODS: A systematic review of PubMed was performed searching from 1946 to March 2020 to identify the literature on chemical peels for AKs. RESULTS: Of the 151 articles identified, 5 met inclusion criteria for review. Four of the reviewed articles demonstrated the efficacy of chemical peels in reducing AK count and minimal adverse effects. In some studies, chemical peels exhibited potential to prevent additional AK formation and development of keratinocyte carcinomas. CONCLUSION: Chemical peels are an efficacious and affordable treatment option for field treatment of AKs. With improved patient tolerance and adherence, chemical peels are an attractive option for field therapy of AKs for both dermatologists and patients.
Subject(s)
Caustics/administration & dosage , Chemexfoliation/statistics & numerical data , Keratosis, Actinic/surgery , Carcinoma, Basal Cell/epidemiology , Carcinoma, Basal Cell/pathology , Carcinoma, Basal Cell/prevention & control , Carcinoma, Squamous Cell/epidemiology , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/prevention & control , Caustics/adverse effects , Chemexfoliation/adverse effects , Humans , Keratosis, Actinic/pathology , Recurrence , Secondary Prevention/methods , Secondary Prevention/statistics & numerical data , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology , Skin Neoplasms/prevention & control , Treatment OutcomeABSTRACT
BACKGROUND: Atopic dermatitis (AD) is a growing burden in all ages. The aim of this study was to compare trial characteristics between pediatric and adult AD trials. METHODS: Data were collected from ClinicalTrials.gov on AD therapeutic trials completed between 2003 and 2019. The trials were classified as pediatrics (mean or median age <18 years of the experimental group participants) or adults. The trials with and without results on ClinicalTrials.gov were searched on PubMed for further data collection. RESULTS: Of 210 trials, 50 (24%) were pediatric trials [mean age: 8.2 ± 4.3 years (SD)] and 160 (76%) were adult trials [mean age 35.2 ± 5.7 years (SD)]. Pediatric and adult trials were equally likely to be randomized controlled trials; however, pediatric trials were more likely to be open-label trials (P < .001) and have no comparator (P < .001). Adult trials were more likely to be industry-funded (95% vs. 80%, P = .001). Any evaluation of drug safety was more likely present in adult trials (83% vs. 60%, P = .001). In trials examining AD severity as an outcome, the Eczema Area and Severity Index (EASI) predominated in adult trials (51% vs. 29%, P < .05) and Scoring Atopic Dermatitis (SCORAD) in pediatric trials (25% vs. 10%, P < .05). CONCLUSION: The results highlight differences in trial design between pediatric and adult AD trials and show a lack of standardization in trial design.
Subject(s)
Dermatitis, Atopic , Eczema , Pediatrics , Adult , Child , Dermatitis, Atopic/drug therapy , Humans , Infant, Newborn , Severity of Illness Index , Treatment OutcomeABSTRACT
BACKGROUND: Chemical peels are applied to the face and neck to improve rhytides and the photoaged appearance of the skin. Peels can be applied to different skin depths depending on the types of chemicals, the volume of solution, and the amount of pressure or friction applied. If a peel is applied too superficially, rhytides will not be removed. If a peel is applied too deeply, scarring or hypopigmentation could occur. OBJECTIVE: To create face and neck depth maps for chemical peeling, which can guide safety when removing rhytides and improving the skin's appearance. MATERIALS AND METHODS: A multicenter retrospective review of records was conducted of patients who underwent phenol-croton oil peeling, from January 1, 2018, to December 31, 2018. Information was collected on facial and neck cosmetic units peeled, peel formula and strength used, outcomes, and complications. RESULTS: A total of 410 patients received deep peels. Two depth maps were created that corresponded to the most common patterns of deep chemical peel applications. CONCLUSION: Different areas of the face and neck are treated with different chemical peel application depths to safely improve rhytides and appearance. Depth maps are created to balance safety and efficacy.
Subject(s)
Chemexfoliation/methods , Dermabrasion/methods , Keratolytic Agents/administration & dosage , Administration, Cutaneous , Adult , Aged , Aged, 80 and over , Chemexfoliation/adverse effects , Croton Oil/administration & dosage , Croton Oil/adverse effects , Dermabrasion/adverse effects , Face/anatomy & histology , Female , Humans , Keratolytic Agents/adverse effects , Male , Middle Aged , Neck/anatomy & histology , Phenol/administration & dosage , Phenol/adverse effects , Retrospective Studies , Skin/anatomy & histology , Skin/drug effects , Skin Aging , Treatment OutcomeABSTRACT
Once considered the standard for deep facial resurfacing, the classical Baker-Gordon phenol-croton oil peel has largely been replaced by formulas with lower concentrations of phenol and croton oil. The improved safety profile of deep peels has ushered in a new era in chemical peeling. Wrinkles can be improved and skin can be tightened with more subtle and natural results. No longer does a deep peel denote "alabaster white" facial depigmentation with complete effacement of wrinkles. Gregory Hetter's research showed that the strength and corresponding depth of penetration of the phenol-croton oil peel can be modified by varying the concentration of croton oil. This second article in this continuing medical education series focuses on the main historical, scientific, and procedural considerations in phenol-croton oil peels.
Subject(s)
Chemexfoliation/methods , Croton Oil/therapeutic use , Dermatologic Agents/therapeutic use , Phenol/therapeutic use , Chemexfoliation/adverse effects , Drug Combinations , Humans , Patient Selection , Skin/pathology , Skin AgingABSTRACT
Chemical peeling, or chemexfoliation, has been used for centuries to improve signs of ultraviolet light-induced sun damage. Over the last 30 years, the science behind chemical peeling has evolved, increasing our understanding of the role of peeling ingredients and treatment indications. The depth of peels is directly related to improved results and to the number of complications that can occur. Key principles for superficial and medium depth peeling are discussed, as well as appropriate indications for these treatments.
Subject(s)
Caustics/therapeutic use , Chemexfoliation/methods , Keratolytic Agents/therapeutic use , Skin Diseases/therapy , Chemexfoliation/adverse effects , Drug Combinations , Ethanol/therapeutic use , Glycolates/therapeutic use , Humans , Lactic Acid/therapeutic use , Phenol/therapeutic use , Resorcinols/therapeutic use , Salicylates/therapeutic use , Salicylic Acid/therapeutic use , Tretinoin/therapeutic use , Trichloroacetic Acid/therapeutic useSubject(s)
Salicylic Acid , Skin Aging , Trichloroacetic Acid , Humans , Trichloroacetic Acid/administration & dosage , Trichloroacetic Acid/therapeutic use , Salicylic Acid/administration & dosage , Salicylic Acid/therapeutic use , Skin Aging/drug effects , Drug Combinations , Female , Middle Aged , Face , Caustics/administration & dosage , Aged , Male , Skin/pathology , Skin/drug effects , Ethanol , Resorcinols , Salicylates , Lactic AcidABSTRACT
BACKGROUND: As the demand for cosmetic treatments increases, it is important for dermatology residents to be educated about and achieve proficiency in dermatologic cosmetic procedures. OBJECTIVE: To assess dermatology residents' educational exposure to cosmetic dermatology. MATERIALS AND METHODS: An anonymous 18-question survey was sent electronically to 1,266 dermatology residents requesting information about cosmetic dermatology training during residency. RESULTS: Two hundred sixty-eight residents responded to the survey (21% response rate). Most residents receive didactic instruction (94%) and hands-on training (91%) on cosmetic dermatology topics during residency. Survey participants in residency programs perceived as supportive of cosmetic dermatology training are more frequently provided lectures (70% vs 31%, p < .001) and procedural training (100% vs 69%, p < .001) in cosmetic dermatology as compared to residents in unsupportive programs. Eighty-nine percent of respondents reported hands-on training as the most effective method for developing proficiency in cosmetic procedures. CONCLUSION: Providing safe and competent patient care should serve as the impetus for expanding cosmetic dermatology education and training for residents.
Subject(s)
Dermatology/education , Internship and Residency , Attitude of Health Personnel , Clinical Competence , Curriculum , Humans , Self-Assessment , Surveys and QuestionnairesSubject(s)
Botulinum Toxins, Type A , Botulinum Toxins , Cosmetic Techniques , Neuromuscular Agents , Face , Humans , Injections , Neurotransmitter AgentsABSTRACT
BACKGROUND: The extent of variability in treatment suggestions for melanocytic lesions made by pathologists is unknown. OBJECTIVE: We investigated how often pathologists rendered suggestions, reasons for providing suggestions, and concordance with national guidelines. METHODS: We conducted a cross-sectional survey of pathologists. Data included physician characteristics, experience, and treatment recommendation practices. RESULTS: Of 301 pathologists, 207 (69%) from 10 states (California, Connecticut, Hawaii, Iowa, Kentucky, Louisiana, New Jersey, New Mexico, Utah, and Washington) enrolled. In all, 15% and 7% reported never and always including suggestions, respectively. Reasons for offering suggestions included improved care (79%), clarification (68%), and legal liability (39%). Reasons for not offering suggestions included referring physician preference (48%), lack of clinical information (44%), and expertise (29%). Training and caseload were associated with offering suggestions (P < .05). Physician suggestions were most consistent for mild/moderate dysplastic nevi and melanoma. For melanoma in situ, 18 (9%) and 32 (15%) pathologists made suggestions that undertreated or overtreated lesions based on National Comprehensive Cancer Network (NCCN) guidelines, respectively. For invasive melanoma, 14 (7%) pathologists made treatment suggestions that undertreated lesions based on NCCN guidelines. LIMITATIONS: Treatment suggestions were self-reported. CONCLUSIONS: Pathologists made recommendations ranging in consistency. These findings may inform efforts to reduce treatment variability and optimize patterns of care delivery for patients.
Subject(s)
Guideline Adherence/statistics & numerical data , Melanoma/therapy , Nevus, Pigmented/therapy , Pathologists/statistics & numerical data , Practice Patterns, Physicians'/statistics & numerical data , Skin Neoplasms/therapy , Clinical Competence , Cross-Sectional Studies , Female , Humans , Liability, Legal , Male , Melanoma/pathology , Middle Aged , Nevus, Pigmented/pathology , Pathologists/education , Practice Guidelines as Topic , Practice Patterns, Physicians'/standards , Self Efficacy , Skin Neoplasms/pathology , United StatesABSTRACT
BACKGROUND: Spitz nevi, atypical Spitz tumors and spitzoid melanomas ('spitzoid lesions') represent controversial and poorly understood cutaneous melanocytic lesions that are difficult to diagnose histologically. It is unknown how these terms are used by pathologists. METHODS: We describe use of Spitz-related terminology using data from the Melanoma Pathology (M-Path) study database comprising pathologists' interpretations of biopsy slides, a nation-wide study evaluating practicing US pathologists' (N = 187) diagnoses of melanocytic lesions (8976 independent diagnostic assessments on 240 total test cases, with 1 slide per case). RESULTS: Most pathologists (90%) used the Spitz-related terminology. However, significant variation exists in which specific lesions were diagnosed as spitzoid and in the corresponding treatment recommendations. Recommendations ranged from 'no further treatment' to 'wide excision of 10 mm or greater' with no category capturing more than 50% of responses. For spitzoid melanoma diagnoses, 90% of pathologists recommended excision with ≥10 mm margin. Pathologists report less confidence in diagnosing these lesions compared with other melanocytic proliferations and are more likely to request second opinions and additional clinical information (all p < 0.05). CONCLUSIONS: Spitzoid lesions are often not classified in any standardized way, evoke uncertainty in diagnosis by pathologists, and elicit variability in treatment recommendations.
Subject(s)
Dermatology/standards , Melanoma/classification , Nevus, Epithelioid and Spindle Cell/classification , Pathologists/standards , Pathology, Clinical/standards , Skin Neoplasms/classification , Humans , Melanoma/diagnosis , Nevus, Epithelioid and Spindle Cell/diagnosis , Skin Neoplasms/diagnosis , Terminology as TopicABSTRACT
BACKGROUND: Mohs micrographic surgery (MMS) is used for treatment of primary and recurrent tumors. Compared with primary tumors, recurrent tumors are often more aggressive. OBJECTIVE: To understand differing characteristics between primary versus recurrent tumors treated by MMS. MATERIALS AND METHODS: The authors conducted a retrospective review of a 12-year period at 1 academic center. Recurrent tumors were defined as recurrent if previously treated with cryotherapy, topical chemotherapeutics, electrodesiccation and curettage, or excision. Statistical analysis was conducted with p ≤ .05 considered significant. RESULTS: A total of 17,971 cases were reviewed, of which 10.5% represented recurrent tumors. Recurrent tumors occurred more commonly in men (ratio 2.2:1). They presented in older individuals (p < .01) and occurred more commonly on the scalp (p < .0001), neck (p < .0001), and trunk (p < .0001). Primary tumors were more commonly located on the periocular (p < .0001), nose (p < .0001), and perioral areas (p < .0001). Squamous cell carcinoma more commonly presented as primary tumors (p = .02) while squamous cell carcinoma in situ more commonly presented as recurrent tumors (p < .001). CONCLUSION: Distinct characteristics separate primary and recurrent tumors treated by MMS. Primary tumors were more commonly located in Area H, compared with recurrent tumors, which were more commonly located in Area M. This suggests appropriate usage of MMS based on appropriate use criteria.
Subject(s)
Mohs Surgery , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/surgery , Aged , Female , Humans , Male , Retrospective StudiesABSTRACT
BACKGROUNDS: The diagnosis of melanoma can be challenging, especially in lesions for which the histopathologic criteria bridge two or more taxonomic categories. Newer genomic analytical methods of fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) have been introduced as ancillary techniques to differentiate benign and malignant melanocytic proliferations. METHODS: We evaluated how pathologists perceive and are incorporating these new cytogenetic testing technologies into their practices. We conducted a study of 207 U.S. pathologists who interpret melanocytic lesions in clinical practice in 10 SEER states. Pathologists were surveyed regarding perceptions and utilization of FISH and/or CGH in their clinical practices. RESULTS: Results showed that 38% of pathologists use FISH and/or CGH in interpreting melanocytic lesions. Pathologists reporting FISH and/or CGH use were significantly younger (p < 0.05), were fellowship trained or board certified in dermatopathology (p < 0.001) and were affiliated with an academic institute (p < 0.001). Pathologists reporting that their colleagues consider them an expert in the assessment of melanocytic lesions were more likely to employ FISH and/or CGH in their practices than non-experts. CONCLUSIONS: Early users of cytogenetic testing technologies in cutaneous pathology are more likely to be younger, affiliated with an academic institution and fellowship trained or board certified in dermatopathology.
Subject(s)
Immunosuppressive Agents/administration & dosage , In Situ Hybridization, Fluorescence , Melanoma , Self Medication , Self Report , Adult , Aged , Female , Humans , Male , Melanoma/diagnosis , Melanoma/drug therapy , Melanoma/pathology , Middle Aged , United StatesABSTRACT
BACKGROUND: An objective tool quantifying the toxicity of 5-fluorouracil (5-FU) from photographs was recently reported, and its reliability was confirmed. OBJECTIVE: The aim of this study was to validate the photograph-based toxicity score. METHODS: Photograph-based toxicity scores of participants assigned to the 5-FU arm of a randomized placebo-controlled trial were tested for correlations with their patient-reported symptom scores and baseline characteristics. RESULTS: Each pair of individual and overall scores of patient-reported symptoms and photograph-based toxicity was correlated at 2 and 4 weeks (correlation coefficient range, 0.34-0.95; P < .001 for all). Older age, more actinic keratoses, previous topical 5-FU use, and more keratinocyte carcinomas on the face and ears in the previous 5 years were correlated with increased 5-FU toxicity at 2 weeks (P < .05). An increase in the total number of 5-FU applications during the trial was correlated with less severe toxicity at 2 weeks (P < .001), but with increased toxicity at 4 weeks (P < .001). CONCLUSION: This study provides evidence for construct validity of the photograph-based 5-FU toxicity score. The tool can be used to objectively measure 5-FU toxicity in clinical or research setting, and it can be a prototype for toxicity measurements of other topical medications.
Subject(s)
Antimetabolites, Antineoplastic/adverse effects , Carcinoma, Squamous Cell/diagnosis , Drug Eruptions/etiology , Ear Neoplasms/diagnosis , Facial Neoplasms/diagnosis , Fluorouracil/adverse effects , Photography , Severity of Illness Index , Administration, Cutaneous , Age Factors , Aged , Antimetabolites, Antineoplastic/administration & dosage , Female , Fluorouracil/administration & dosage , Humans , Keratosis, Actinic/drug therapy , Male , Retreatment , Risk Factors , Skin Cream/adverse effectsABSTRACT
PURPOSE: To provide information from a literature review about the prevention, recognition, and treatment for contact dermatitis. TARGET AUDIENCE: This continuing education activity is intended for physicians and nurses with an interest in skin and wound care. OBJECTIVES: After participating in this educational activity, the participant should be better able to:1. Identify signs and symptoms of and diagnostic measures for contact dermatitis.2. Identify causes and risks for contact dermatitis.3. Select appropriate treatment for contact dermatitis and its prevention. ABSTRACT: Contact dermatitis to wound care products is a common, often neglected problem. A review was conducted to identify articles relevant to contact dermatitis.A PubMed English-language literature review was conducted for appropriate articles published between January 2000 and December 2015.Contact dermatitis is both irritant (80% of cases) or allergic (20% of cases). Frequent use of potential contact allergens and impaired barrier function of the skin can lead to rising sensitization in patients with chronic wounds. Common known allergens to avoid in wound care patients include fragrances, colophony, lanolin, and topical antibiotics.Clinicians should be cognizant of the allergens in wound care products and the potential for sensitization. All medical devices, including wound dressings, adhesives, and bandages, should be labeled with their complete ingredients, and manufacturers should be encouraged to remove common allergens from wound care products, including topical creams, ointments, and dressings.